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Calcium-binding protein S100A9 (MRP-14) induces antinociceptive eﬀect in an experimental model of painful sensibility and
participates of antinociception observed during neutrophilic peritonitis induced by glycogen or carrageenan in mice. In this study,
the direct antinociceptive role of the protein S100A9 in neutrophilic cell-free exudates obtained of mice injected with glycogen was
investigated. Mice were intraperitoneally injected with a glycogen solution, and after 4, 8, 24, and 48 hours, either the pattern of
cell migration of the peritoneal exudate or the nociceptive response of animals was evaluated. The glycogen-induced neutrophilic
peritonitisevokedantinociception4and8hoursafterinoculationoftheirritant.Peritonealcell-freeexudates,collectedindiﬀerent
times after the irritant injection, were transferred to naive animals which were submitted to the nociceptive test. The transference
of exudates also induced antinociceptive eﬀect, and neutralization of S100A9 activity by anti-S100A9 monoclonal antibody totally
reverted this response. This eﬀect was not observed when experiments were made 24 or 48 hours after glycogen injection. These
results clearly indicate that S100A9 is secreted during glycogen-induced neutrophilic peritonitis, and that this protein is respon-
sible by antinociception observed in the initial phase of inﬂammatory reaction. Thus, these data reinforce the hypothesis that the
calcium-binding protein S100A9 participates of the endogenous control of inﬂammatory pain.
Copyright © 2006 Rosana L. Pagano et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Neutrophils, monocytes, and macrophages secret a variety of
biologically active products involved in distinct pathophys-
iologic types of response. That is the case of the calcium-
binding proteins S100A8 and S100A9 [1], both members
of the family of the S100 proteins [2], which are expressed
in diﬀerentiating cells of the myeloid lineage, in mature
neutrophils and monocytes, but absent in normal tissue
macrophages and lymphocytes [3, 4].
The S100A8/A9 proteins comprise 45% of the total pro-
teins in the cytosol of neutrophils and 1% in monocytes [5],
and can be found in a complex form called calprotectin [6].
S100A8andS100A9proteinsarealsodescribedasp8andp14
[7], L1 light and heavy chain [8], calgranulin A and B [9],
and MRP-8 and MRP-14 [10], respectively. Under inﬂam-
matory conditions and/or upon calcium mobilization they
are translocated from the cytosol to the cytoskeleton and to
cell plasma membrane [11, 12]. It has been demonstrated
that both proteins are secreted by activated monocytes via a
tubulin and PKC-dependent pathway [13]. In addition, the
heterodimer of these proteins binds arachidonic acid with
high aﬃnity in a calcium-dependent manner [14].
Although little is known about the biological function of
S100A8/A9, it has been demonstrated that in vitro the cal-
protectin has an antimicrobial eﬀect on several micro organ-
isms [6, 15], and induces apoptosis of various tumour cells
or normal ﬁbroblasts in a zinc-reversible manner [16, 17].
S100A8/A9 complex is found in high concentrations in body
ﬂuids of patients with acute and chronic diseases such as
chronic bronchitis, cystic ﬁbrosis, and rheumatoid arthritis
[18], making this complex a useful biomarker of inﬂamma-
tory diseases [19]. An anti-inﬂammatory eﬀect of this com-
plex in a model of adjuvant-induced arthritis in the rat was
reported [20], suggesting a possible extra cellular role for
these proteins.
Independent expression and functioning of S100A9 pro-
tein have also been observed [10, 21]. This protein regulates
neutrophil adhesion to ﬁbrinogen, selectively activates the
β2 integrin, Mac-1 [22] and deactivates BCG-activated peri-
toneal macrophages [23]. We have demonstrated a marked
antinociception eﬀect of S100A9 in a model of inﬂammatory2 Mediators of Inﬂammation
pain [24]. Further, antinociception was detected in the
course of acute neutrophilic peritonitis induced by glycogen
andcarrageenan,whichwererevertedbythetreatmentofan-
imals with a monoclonal antibody anti-S100A9, suggesting
that neutrophils in acute inﬂammation down-regulate the
nociceptive response via S100A9 activity [24, 25]. Recently,
we demonstrated that the C-terminus of S100A9 murine in-
hibits the spreading and phagocytic activities of adherent
peritoneal cells [26], cells involved in the nociceptive re-
sponse during the model of abdominal contortions in mice
[27]. Based on these data, in the present study we investi-
gated the antinociceptive eﬀect of the neutrophilic cell-free
exudate induced by glycogen, and the role of the calcium-
binding protein S100A9 in this eﬀect.
MATERIALS AND METHODS
Animals
Outbred male mice from the Swiss strain, weighing 20–25g,
were used throughout this study. The animals were main-
tained under controlled light (12/12 hours) and temperature
(22
￿ 2
ÆC) with free access to food and water. Throughout
the experiments, the animals weremanagedusing the princi-
ples and guidelines published by the Committee forResearch
andEthicalIssueoftheInternationalAssociationforStudyof
Pain [28].
Glycogen-inducedperitonitis
Micewereintraperitoneally(IP)injectedwith500μLofa5%
solution of oyster glycogen type II (Sigma, Mo, USA) pre-
pared in sterile saline. Control animals were injected only
with saline. After 4, 8, 24, or 48 hours of glycogen solution
inoculation, mice were either sacriﬁced, in a CO2 chamber,
to evaluation of the peritoneal ﬂuid or submitted to the no-
ciceptive test.
Nociceptionevaluationbythewrithingtest
The mouse writhing test used was based on the method of
Koster et al [29]. The abdominal contortions resulting from
intraperitoneal injection of acetic acid (0.6%; Merck, Darm-
stadt,Germany)atadosageof60mg/Kg(v/v)consistofcon-
tractionoftheabdominalmuscleswithstretchingofthehind
limb.Thenumberofabdominalcontortionswascountedcu-
mulatively over a period of 20 minutes after acetic acid injec-
tion. The antinociceptive activity was expressed as the reduc-
tion in number of abdominal contortions in treated as com-
pared to control animals, injected with saline or only with
acetic acid.
Inﬂammatorycellscharacterizationandcell-free
exudatecollection
Mice injected with glycogen solution or sterile saline, af-
ter diﬀerent times, were sacriﬁced in a CO2 chamber and
theirperitonealcavitieswashedwith5mLofcoldphosphate-
buﬀered saline (PBS) pH 7.4. After a gentle massage of the
abdominal wall, the peritoneal ﬂuid was collected and the
total and diﬀerential counts of leukocytes were determined.
The leukocyte cell-free exudate supernatant was obtained
from the peritoneal ﬂuid after two individual centrifuga-
tions (2000rpm/10 min, 5
ÆC). Supernatants assembled for
each time and group of the treatment were frozen (
￿20
ÆC)
and, in the moment of assay, were injected in naive animals
(200μL/cavity) 30 minutes before of the evaluation of the
antinociceptive activity.
Monoclonalantibody(mAb)
Mouse mAb (IgG1) antihuman S100A9 (anti-MRP-14; BMA
BiomedicalsAG,Switzerland)andgoatmAbantimouseIgG1
(Sigma, Mo, USA) were used.
AdsorptionofS100A9oftheinﬂammatory
cell-freeexudates
mAb antimouse IgG1 (1mg/mL) in carbonate buﬀer (pH
9.5) was distributed in wells of 96-well ELISA plates
(100μL/well) and incubated overnight at 4
ÆC. These solu-
tions were removed and the wells were ﬁlled with 1% bovine
seric albumine (BSA) in PBS (200μL/well) for 12 hours at
4
ÆC. The wells were washed (three times) with PBS fol-
lowed by Twin 20 (0.5%) in PBS (two times) and replaced
with 200μL of supernatants obtained from the inﬂamma-
tory cell-free exudate, after 4 or 8 hours of glycogen inocula-
tion, previously incubated with antihuman S100A9 (mouse
IgG1 isotype). The supernatants were adsorbed in tripli-
cate on antimouse IgG1-coated wells in 2-hour intervals,
and ﬁnally incubated on coated wells for 18 hours at 4
ÆC.
These supernatants were frozen (
￿20
ÆC), and in the mo-
mentofassaywereintraperitoneallyinjectedinnaiveanimals
(200μL/cavity), 30 minutes before the nociceptive test.
Statisticalanalysis
Results are expressed as mean
￿ standard errors of means
(SEM) and were compared by the Student t test or by analy-
sis of variance [30], followed by Duncan’s test [31]. A proba-
bility level of less than .05 was taken as signiﬁcant (P<. 05).
RESULTS
Glycogen-inducedleukocytemigration
As we had previous evidence that neutrophils, via protein
S100A9 (MRP-14), mediate the antinociceptive eﬀect in a
neutrophilicperitonitisinducedbyglycogen[24],weﬁrstde-
cidedtoestablishtheleukocyteinﬂuxinducedbytheirritant.
Results conﬁrmed our data and showed that the IP injection
of glycogen induced a signiﬁcant number of polymorphonu-
clear cells in the peritoneal cavity of animals when com-
pared with controls. The maximal number of these cells was
observed 8 hours after the irritant injection (Figure 1(a)).
The number of mononuclear cells signiﬁcantly decreased
4 and 8 hours after glycogen injection. Conversely it wasRosana L. Pagano et al 3
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Figure 1: Kinetics of leukocyte inﬂux to peritoneal cavity of mice after IP injection of a glycogen solution (5%, 500μL/animal). Number
of polymorphonuclear cells (PMN cells; (a)) and mononuclear cells (MN cells; (b)). Results are expressed in absolute numbers obtained in
relation to the total number of collected cells. Values represent mean values
￿ SEM for 8–16 animals for each experimental time.
￿P<. 05
in comparison with values obtained in control animals.
showed an increase of these cells after 48 hours of irritant
treatment (Figure 1(b)).
Glycogen-inducedantinociceptiveeffect
To conﬁrm the antinociceptive response observed after in-
traperitonealglycogeninjection,wesubmittedtheanimalsto
the writhing test after glycogen injection. Results showed an
antinociceptive eﬀect, 4 and 8 hours after the irritant treat-
ment, when compared with animals previously injected with
saline or acetic acid alone (42 and 47% inhibition, resp.)
(Figure 2). It was also observed that the injection of glycogen
solution did not induce changes in the nociceptive response
of animals after 24 or 48 hours of treatment when compared
with control animals (Figure 2).
Transferenceofinﬂammatorycell-freeexudate
To investigate if the antinociceptive factor was secreted by
migrated leukocytes after the glycogen inoculation, naive an-
imals were injected with cell-free exudate, obtained after dif-
ferent time intervals, and after 30 minutes evaluated in the
writhing test. Results show that the transference of cell-free
exudates induced antinociceptive eﬀect when they were ob-
tained 4 or 8 hours after glycogen injection (40 and 45% in-
hibition, resp.). The treatment of mice either with cell-free
exudateobtained24or48hoursaftertheirritantinjectionor
with the supernatants obtained of animals injected only with
saline did not inﬂuence the nociceptive response (Figure 3).
AdsorptionofS100A9ofthecell-freeexudates
withantinociceptiveeffect
To investigate whether the antinociceptive eﬀect induced
by cell-free exudates obtained after 4 or 8 hours of the
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Figure 2: Eﬀect of glycogen on painful sensibility of mice evaluated
in the writhing test. The test was applied in diﬀerent times after IP
injection of glycogen (5%, 500μL/animal). Controls were injected
only with acetic acid. Values represent the mean
￿ SEM of 8–16 an-
imals for each group.
￿P<. 05 in comparison with values obtained
in control animals.
glycogen injection was due to secretion of the S100A9 pro-
tein, mice were treated with cell-free exudates adsorpted of
this protein. Results show that adsorption of S100A9 from
these supernatants, using mAb anti-S100A9 (anti-MRP-14),
reverted the observed antinociceptive response (Figure 4).
Treatment of animals with this mAb alone or with nonre-
lated rat IgG, previously to the acetic acid injection, did not
alter the nociceptive response when compared with control
animals (data not shown).4 Mediators of Inﬂammation
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Figure 3: Eﬀect of cell-free exudates obtained 4, 8, 24 or 48hours
after glycogen injection (Glycogen Sn) in naive animals submitted
to the writhing test. The exudate supernatants (200μL/cavity) were
injected 30minutes before the test. Animals injected with super-
natants obtained after saline injection (Saline Sn) were also evalu-
ated. Controls were injected only with acetic acid. Values represent
the mean
￿ S E Mo f8 – 1 6a n i m a l sf o re a c hg r o u p .
￿P<. 05 in com-
parison with values obtained in control animals.
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Figure 4: Eﬀect of adsorption of S100A9 of cell-free exudates ob-
tained 4 or 8hours after glycogen injection (Gly Sn + anti-S100A9)
in naive animals submitted to the writhing test. The exudate su-
pernatants (200μL/cavity) were injected 30 minutes before the test.
Animals injected with exudate supernatants not treated with mAb
anti-S100A9 (Gly Sn) were also evaluated. Controls were injected
only with acetic acid. Values represent the mean
￿ SEM of 8–16 an-
imals for each group.
￿P<. 05 in comparison with values obtained
in control animals.
DISCUSSION
Mediators secreted during inﬂammatory response are in-
volved in the control of painful response. In regard to that,
interleukin-4 (IL-4), IL-10, and IL-13 have the propriety of
limiting the inﬂammatory hyperalgesia inhibiting the pro-
duction of proinﬂammatory cytokines [32–35].
Proteins S100A8 and S100A9 comprise an important
group of proteins expressed by phagocytes during inﬂamma-
toryresponse[36],andareinvolvedintheﬁrstlineofdefence
a g a i n s tt h i st y p er e s p o n s e[ 37]. The S100A9 protein, speciﬁ-
cally, play a role in the inﬂammatory reaction to lipopolis-
sacarides by inducing the release of neutrophils from the
bone marrow and directing their migration to the inﬂamma-
tory site, thus suggesting that it could represent a new class
of early cytokines involved in innate immune responses [38].
According to the evidence suggesting that S100A9 is a
proinﬂammatory protein [36], our group have proposed
that this protein is endowed with antinociceptive activity
in inﬂammatory pain model [24]. It was also observed the
participation of S100A9 in antinociception observed during
acute inﬂammatory peritonitis induced by glycogen or car-
rageenan in mice [24, 25]. Recently, we demonstrated that
the C-terminus of this protein is involved either with the
antinociceptive eﬀect on hyperalgesia induced by protease
[39], or with the inhibition of the phagocytosis and spread-
ing activities of adherent peritoneal cells [26], cells respon-
sible by the writhing nociceptive response [27]. Based on
these data, we decided to investigate if the S100A9 is secreted
during glycogen-induced neutrophilic peritonitis, and if this
protein directly acts in the antinociceptive eﬀect observed in
this model of acute inﬂammation.
A direct correlation between the number of neutrophils
in the peritoneal cavity after glycogen treatment and the
maximal antinociceptive response was observed, as previ-
ously described [24]. In agreement with data obtained by
Pagano et al [25] our results strongly suggest that these cells
could be involved in the control of inﬂammatory pain, pos-
sibly through S100A9 protein action.
The antinociceptive eﬀect observed after leukocyte cell-
free exudate transfer, obtained after 4 or 8 hours of glyco-
gen injection to naive animals, conﬁrmed that migrated cells
secrete the antinociceptive factor in acute phase of inﬂam-
matory process. The demonstration that the antinociception
observed was mediated by S100A9 action was conﬁrmed by
adsorption of this protein in the cell-free exudates obtained
4 or 8 hours after the irritant injection.
The participation of neutrophils in the observed antino-
ciceptive eﬀect, as previously shown [24, 25], can be rein-
forced by results here shown with the cell-free exudates ob-
tained24and48hoursaftertheglycogeninjection,sincethey
did not induce antinociception with a decrease of polymor-
phonuclear cells and concomitant increase of mononuclear
cells.
The mechanism by which S100A9 induces antinocicep-
tion was not established yet. However, taking into account
thatS100A9deactivatesactivatedmacrophages[23],andthat
the C-terminus of S100A9 murine inhibits phagocytosis and
spreading activities of adherent peritoneal cells [26], cells
involved in painful response by release of hyperalgesic cy-
tokines in the abdominal contortions model [27], the eﬀect
observed by S100A9 could be related with macrophage acti-
vation with consequent inhibition of secretion of algogenicRosana L. Pagano et al 5
factors by these cells. On the other hand, S100A9 could alter
the phenotype of macrophages for an “anti-inﬂammatory
cell”increasingthereleaseofinhibitorycytokines,suchasIL-
4 and IL-10, which are involved in inﬂammatory pain con-
trol.
AlthoughseveralreportsdescribethepresenceofS100A9
in the initial phase of inﬂammatory response [36, 37], less is
known about its biological role in nociception process. Our
data strongly indicate that neutrophil-secreted S100A9 pro-
tein participates in inﬂammatory pain control.
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